Telormedix and Swiss TPH Institute Sign Malaria and Buruli Ulcer Collaboration

BIOGGIO, Switzerland--(BUSINESS WIRE)--Telormedix, a clinical stage biopharmaceutical company using targeted immunity to treat cancer and other diseases, today announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix’s adjuvant, TMX-201, in connection with immunization for Malaria and Buruli Ulcer.

MORE ON THIS TOPIC